tiprankstipranks
Pacira (CH:82P)
NASDAQ:82P
Switzerland Market
82P
Pacira Pharmaceuticals
RESEARCH TOOLSreports

Pacira Pharmaceuticals (82P) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

82P Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
3 Buy
2 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Pacira
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

82P Stock 12 Month Forecast

Average Price Target

$23.95
Based on 5 Wall Street analysts offering 12 month price targets for Pacira Pharmaceuticals in the last 3 months. The average price target is $23.95 with a high forecast of $30.59 and a low forecast of $19.32. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$30.59Average Price Target$23.95Lowest Price Target$19.32
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:82P
Jenna Davidner
Barclays
Barclays
CHF20.12
Hold
―
Reiterated
05/14/26
Barclays Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)
H.C. Wainwright Analyst forecast on CH:82P
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
CHF30.59
Buy
―
Reiterated
05/04/26
H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)
Needham Analyst forecast on CH:82P
Serge Belanger
Needham
Needham
CHF24.15→CHF25.76
Buy
―
Reiterated
05/01/26
Analysts Are Bullish on Top Healthcare Stocks: Irhythm Technologies (IRTC), Pacira Pharmaceuticals (PCRX)
Truist Financial Analyst forecast on CH:82P
Les Sulewski
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
RBC Capital Analyst forecast on CH:82P
Douglas Miehm
RBC Capital
RBC Capital
CHF17.71→CHF19.32
Hold
―
Reiterated
04/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Merit Medical Systems (NASDAQ: MMSI) and Ardelyx (NASDAQ: ARDX)
J.P. Morgan Analyst forecast on CH:82P
Hardik Parikh
J.P. Morgan
J.P. Morgan
CHF18.51
Sell
―
Reiterated
03/20/26
J.P. Morgan Sticks to Their Sell Rating for Pacira Pharmaceuticals (PCRX)
Jefferies Analyst forecast on CH:82P
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF28.98
Buy
―
Reiterated
01/09/26
Jefferies Remains a Buy on Pacira Pharmaceuticals (PCRX)
Canaccord Genuity Analyst forecast on CH:82P
Gary Nachman
Canaccord Genuity
Canaccord Genuity
―
Hold
―
Reiterated
10/06/25
Raymond James Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:82P
Jenna Davidner
Barclays
Barclays
CHF20.12
Hold
―
Reiterated
05/14/26
Barclays Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)
H.C. Wainwright Analyst forecast on CH:82P
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
CHF30.59
Buy
―
Reiterated
05/04/26
H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)
Needham Analyst forecast on CH:82P
Serge Belanger
Needham
Needham
CHF24.15→CHF25.76
Buy
―
Reiterated
05/01/26
Analysts Are Bullish on Top Healthcare Stocks: Irhythm Technologies (IRTC), Pacira Pharmaceuticals (PCRX)
Truist Financial Analyst forecast on CH:82P
Les Sulewski
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
RBC Capital Analyst forecast on CH:82P
Douglas Miehm
RBC Capital
RBC Capital
CHF17.71→CHF19.32
Hold
―
Reiterated
04/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Merit Medical Systems (NASDAQ: MMSI) and Ardelyx (NASDAQ: ARDX)
J.P. Morgan Analyst forecast on CH:82P
Hardik Parikh
J.P. Morgan
J.P. Morgan
CHF18.51
Sell
―
Reiterated
03/20/26
J.P. Morgan Sticks to Their Sell Rating for Pacira Pharmaceuticals (PCRX)
Jefferies Analyst forecast on CH:82P
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF28.98
Buy
―
Reiterated
01/09/26
Jefferies Remains a Buy on Pacira Pharmaceuticals (PCRX)
Canaccord Genuity Analyst forecast on CH:82P
Gary Nachman
Canaccord Genuity
Canaccord Genuity
―
Hold
―
Reiterated
10/06/25
Raymond James Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacira Pharmaceuticals

3 Months
Les SulewskiTruist Financial
Success Rate
5/18 ratings generated profit
28%
Average Return
-11.86%
Copying Les Sulewski's trades and holding each position for 3 Months would result in 27.78% of your transactions generating a profit, with an average return of -11.86% per trade.
1 Year
Les SulewskiTruist Financial
Success Rate
5/18 ratings generated profit
28%
Average Return
-30.86%
Copying Les Sulewski's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -30.86% per trade.
2 Years
Les SulewskiTruist Financial
Success Rate
5/18 ratings generated profit
28%
Average Return
-32.20%
Copying Les Sulewski's trades and holding each position for 2 Years would result in 27.78% of your transactions generating a profit, with an average return of -32.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

82P Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
4
4
3
3
3
Buy
5
4
3
3
3
Hold
2
2
3
3
2
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
11
11
10
10
8
In the current month, 82P has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 82P average Analyst price target in the past 3 months is 23.95.
Each month's total comprises the sum of three months' worth of ratings.

82P Financial Forecast

82P Earnings Forecast

Next quarter’s earnings estimate for 82P is $0.52 with a range of $0.41 to $0.60. The previous quarter’s EPS was $0.48. 82P beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 82P has Performed in-line its overall industry.
Next quarter’s earnings estimate for 82P is $0.52 with a range of $0.41 to $0.60. The previous quarter’s EPS was $0.48. 82P beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 82P has Performed in-line its overall industry.

82P Sales Forecast

Next quarter’s sales forecast for 82P is $152.25M with a range of $150.38M to $153.49M. The previous quarter’s sales results were $141.36M. 82P beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 82P has Performed in-line its overall industry.
Next quarter’s sales forecast for 82P is $152.25M with a range of $150.38M to $153.49M. The previous quarter’s sales results were $141.36M. 82P beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 82P has Performed in-line its overall industry.

82P Stock Forecast FAQ

What is CH:82P’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacira’s 12-month average price target is 23.95.
    What is CH:82P’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:82P, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Pacira a Buy, Sell or Hold?
        Pacira has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Pacira’s share price target?
          The average share price target for Pacira is 23.95. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $30.59 ,and the lowest forecast is $19.32. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Pacira?
            Pacira’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
              How can I buy shares of Pacira?
              To buy shares of CH:82P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.